key: cord-0969544-94le8klb
authors: Rajae, Alkouh; Manal, Merbouh; Ghizlane, El Aidouni; Amine, Bouabdlaoui; I.Zaid; Houssam, Bkiyar; Yassine, Mabrouk; Brahim, Housni
title: Ischemic stroke revealing COVID-19 infection: Case report
date: 2021-10-05
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102912
sha: 18a7aaa8a6ae398c42852b39e23236066ee6fd6e
doc_id: 969544
cord_uid: 94le8klb

INTRODUCTION: SARS-COV-2 viral infection primarily targets the respiratory system with a clinical picture that varies from simple symptoms to respiratory distress syndrome requiring hospitalization in the intensive care unit; SARS-CoV-2 also has neuro-invasive capabilities and could spread from the respiratory system to the central nervous system. Recently, some patients with COVID-19 have been shown to have neurological symptoms such as headache, anosmia, dysgeusia, dizziness, impaired consciousness, and ischemic stroke. CASE PRESENTATION: we describe a case of ischemic stroke as the main presentation of COVID-19 in a 68 years old man with no previous history, without any associated respiratory signs; clinical examination revealed left hemiparesis with dysarthria and left facial paralysis, NIHSS score was at 11, the brain CT scan performed 1h30min later, completed by a brain MRI that came back in favor of right frontal, temporal and parietal ischemic stroke. The decision of thrombolysis was indicated in urgency, and the patient benefited from thrombolysis, which proceeded without incidents; the outcome was favorable with regression of symptoms. Ischemic stroke has been widely described among the thromboembolic complications of COVID-19, but only a few papers have reported it as a primary manifestation of COVID-19. CONCLUSION: SARS-COV 2 infection can spread from the respiratory system to the central nervous system, resulting in an inflammatory response and excessive secretion of inflammatory markers, leading to ischemic stroke.

1 Introduction:

SARS-COV-2 viral infection primarily targets the respiratory system with a clinical picture that varies from simple symptoms to respiratory distress syndrome requiring hospitalization in the intensive care unit; SARS-CoV-2 also has neuro-invasive capabilities and could spread from the respiratory system to the central nervous system. Recently, some patients with COVID-19 have been shown to have neurological symptoms such as headache, anosmia, dysgeusia, dizziness, impaired consciousness, and ischemic stroke.

we describe a case of ischemic stroke as the main presentation of COVID-19 in a 68 years old man with no previous history, without any associated respiratory signs; clinical examination revealed left hemiparesis with dysarthria and left facial paralysis, NIHSS score was at 11, the brain CT scan performed 1h30min later, completed by a brain MRI that came back in favor of right frontal,temporal and parietal ischemic stroke. The decision of thrombolysis was indicated in urgency, and the patient benefited from thrombolysis, which proceeded without incidents; the outcome was favorable with regression of symptoms.

Ischemic stroke has been widely described among the thromboembolic complications of COVID-19, but only a few papers have reported it as a primary manifestation of COVID-19

SARS-COV 2 infection can spread from the respiratory system to the central nervous system, resulting in an inflammatory response and excessive secretion of inflammatory markers, leading to ischemic stroke.

COVI-19, ischemic stroke, thrombolysis, case report Sars-cov-2: Severe acute respiratory Syndrome Coronavirus 2. SARS COV 2 viral infection may manifest by respiratory symptoms or other symptoms, such as cardiovascular manifestations. In addition, SARS COV 2 also has neurological invasive capabilities and could spread from the respiratory system to the central nervous system (1, 2) . A paper published in New York reports 5 cases of ischemic stroke in a young age population with no apparent risk factors(3); theory suggests that SARS COV 2 facilitates the recruitment of inflammatory cells into blood vessels, which leads to the release of inflammatory markers and cytokines that subsequently activate coagulation.

In this article, we will represent a case of a 68 years old patient admitted to the emergency department in the setting of a thrombolysis alert for left hemiparesis with dysarthria and left facial paralysis whose explorations revealed a right frontal temporal and parietal ischemic stroke with SARS COV 2 infection.

Case interest: ischemic stroke is a rare clinical presentation revealing SARS COV 2 infection.

Here we report the case of a 68 years old patient without any notable pathological history, admitted to the emergency department of Mohammed VI university hospital in OUJDA with sudden onset of hemiparesis, dysarthria, and left facial paralysis.

On arrival, the patient was unconscious (Eye opening:3/4, Motor response:5/6, Verbal respone:4/5), he was hemodynamically stable with a blood pressure of 130/80mmHg, heart rate of 84 bpm, eupneic with a respiratory rate of 14 breaths/min, and oxygen saturation of 90% on room air, the temperature was at 37.2°C, neurological examination showed the weakness of the left half body and muscle strength of the limb was grade 2/5, In addition, he has a difficulty of spelling words with a deviation of the tongue, tendon reflexes were symmetrically normal.

A cerebral CT scan with complementary cerebral MRI came back in favor of a right frontal temporal and parietal ischemic stroke (Fig 1:A,B) ; the decision of thrombolysis was urgently indicated with 90 mg of actilyse for a weight of 96 Kg (9mg loading dose,81 mg maintenance dose) without any incident, then the patient was transferred to the neurology department, at day 2 of his hospitalization, he had effort dyspnea with dry cough and desaturation at 70%,so it was decided to transfer the patient in ICU with the realization of chest CT scan for suspicion of pneumonia, the results showed bilateral alveolarinterstitial pneumopathy with ground glass and nodular opacities in favor of SARS COV 2, the damage was estimated between 50-75% (fig2), polymerase chain reaction(PCR) for SARS COV 2 infection was positive.

Laboratory tests showed signs of the inflammatory response, white blood cells counted 12490/µl, Creactive protein (CRP) at 223 mg/l, lymphopenia at 980/µ ferritin was elevated at 6017.55µg/, procalcitonin (PCT) at 1.89 ng/ml, interleukin-6(IL-6) at 213 pg/ml, D-Dimer at 2.3, fibrinogen 5.4 g/l, the result of laboratory test for cardiac, renal, liver functions were normal. As part of the etiological workup, the transthoracic echocardiography (TTE) was normal with preserved global Left ventricle systolic 3 function (visual FE: 50%), arteriography also showed no abnormalities anticoagulation was interrupted at this stage because of the risk of hemorrhagic transformation. The patient received COVID-19 national protocol treatment: Vitamin C 1g twice a day, zinc 45mg twice a day, azithromycin 500mg on the first day, then 250mg for four days, vitamin D 25000 IU/week, proton pump inhibitor (PPI) 40mg a day, Dexamethason 16mg a day for ten days.

The outcome was favorable, brain CT scan on the second day after stroke revealed no signs of hemorrhage, after five days, there was an improvement in respiratory and neurological symptoms, oxygen saturation was 90% using 2l of nasal cannula, the neurological examination revealed (Eye opening:4/4, Motor response:6/6, Verbal respone:5/5) with the improvement of muscle strength at 4/5, also noting a regression of biological inflammation markers. The patient was very satisfied after the improvement in his clinical condition and was then transferred to the neurological department.

This case report followed care guidelines [9] . , acute cardiac problems, and multiple organ dysfunction (4); in addition, SARS COV 2 also has neurological invasive capabilities and could spread from the respiratory system to the central nervous system (1,2), due to excessive inflammation, immobilization, hypoxia and diffuse intravascular coagulation (5) .In the literature, authors have described the association between COVID-19 infection and thromboembolic complications, including ischemic stroke (3); a recent Chinese study demonstrated that acute cerebrovascular disease is not uncommon in patients with COVID-19 (6).they reported 221 patients with COVID-19 (5%) who developed acute ischemic stroke, large artery stroke was also diagnosed in five among 206 patients with SARS in Singapore (7), in a case series, four patients with COVID-19 were reported to have ischemic stroke simultaneously (4).

Ischemic stroke as an unusual main manifestation of COVID-19 was first described in a 79 years old man with previous medical history admitted to Hubei Provincial Traditional Chinese medicine hospital for ischemic stroke and later diagnosed with COVID-19 (8) , which is the case in our patient who had no comorbidities or cardiovascular risk factors, hemiparesis was the main symptom that revealed ischemic stroke in the 2 cases, and therefore should indicate possible neurological involvement of COVID 19 infection. As is well known, ischemic stroke is one of the most important causes of neurological morbidity and mortality worldwide; it can be the result of cardiac embolism, small vessel occlusion, and atherosclerosis; consequent neurological inflammation can be observed that causes ischemic brain damage (9) . Diagnosis is usually based on presenting symptoms, data from clinical examination and brain imaging, other imaging tests (CT, MRI, TTE, Doppler, Angiography), and blood tests are performed to identify the cause of stroke.

Treatment may include medications to dissolve clots or make the blood less likely to clot, as well as surgery or angioplasty to open blocked arteries; intravenous thrombolysis is the only approved systemic impact treatment for patients in acute ischemic stroke (10).Approximately one-third of patients who have suffered an ischemic stroke recover nearly full function.

Neurological involvement, including ischemic stroke, may be the primary manifestation of COVID-19 infection; clinicians should be aware of that atypical manifestation even in the absence of respiratory tract symptoms. This article has no funding resources.

the article type (case report), the ethical approval was not necessary This is not an original research project involving human participants in an interventional or an observational study but a case report. This registration is was not required.

J o u r n a l P r e -p r o o f

Epidemiology, Pathogenesis, and Control of COVID-19

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Large-Vessel Stroke as a PresentingFeature of Covid-19 in the Young

Coexistence of COVID-19 and acute ischemic stroke report of four cases Abdulkadir TUNÇ a,⇑ , Yonca ÜNLÜBAS a , Murat ALEMDAR a , Enes AKYÜZ b aClinic of Neurology

Incidence of thrombotic complications in criticallyill ICU patients with COVID-19

Clinical time course of COVID-19, itsneurological manifestation and somethoughts on its management

Strokes, thromboembolicevents, and IVIg: rare incidents blemish an excellent safety record

The impact of COVID-19 on ischemic stroke Pan Zhai1

Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches

Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline

Gagnier CARE guidelines for case reports: explanation and elaboration document

Highlights :-COVID-19 can be revealed by ischemic stroke -Ischemic stroke has been widely described among the thromboembolic complications of COVID-19, but only a few papers have reported it as a primary manifestation of COVID-19 -SARS-COV 2 infection can spread from the respiratory system to the central nervous system, resulting in an inflammatory response and excessive secretion of inflammatory markers, leading to ischemic stroke.J o u r n a l P r e -p r o o f

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.The ethical committee approval was not required give the article type ( case report ) .However , the written consent to publish the clinical data of the patients was given and is available to check by the handling editor if needed .J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. This is not an original research project involving human participants in an interventional or an observational study but a case report. This registration was not required .

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish